{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:07:15Z","timestamp":1791295635719,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T00:00:00Z","timestamp":1457395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000278","name":"United Kingdom's Department for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.vaccine.2016.02.075","type":"journal-article","created":{"date-parts":[[2016,3,12]],"date-time":"2016-03-12T09:15:26Z","timestamp":1457774126000},"page":"2887-2894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":215,"title":["Status of vaccine research and development for Shigella"],"prefix":"10.1016","volume":"34","author":[{"given":"Sachin","family":"Mani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wierzba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard I.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.02.075_bib0390","first-page":"651","article-title":"Global burden of Shigella infections: implications for vaccine development and implementation of control strategies","volume":"77","author":"Kotloff","year":"1999","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0395","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case\u2013control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0400","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/S2214-109X(15)00151-5","article-title":"Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED)","volume":"3","author":"Platts-Mills","year":"2015","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0405","doi-asserted-by":"crossref","first-page":"e72788","DOI":"10.1371\/journal.pone.0072788","article-title":"Global causes of diarrheal disease mortality in children <5 years of age: a systematic review","volume":"8","author":"Lanata","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0410","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0415","doi-asserted-by":"crossref","first-page":"e2705","DOI":"10.1371\/journal.pntd.0002705","article-title":"Estimating diarrheal illness and deaths attributable to Shigellae and enterotoxigenic Escherichia coli among older children, adolescents, and adults in South Asia and Africa","volume":"8","author":"Lamberti","year":"2014","journal-title":"PLOS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0420","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0425","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0430","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0435","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/JCM.02713-12","article-title":"Quantitative PCR for detection of Shigella improves ascertainment of Shigella burden in children with moderate-to-severe diarrhea in low-income countries","volume":"51","author":"Lindsay","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0440","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1371\/journal.ppat.0030147","article-title":"Pathogenesis, virulence, and infective dose","volume":"3","author":"Schmid-Hempel","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0445","doi-asserted-by":"crossref","first-page":"e62029","DOI":"10.1371\/journal.pone.0062029","article-title":"Changing emergence of Shigella sero-groups in Bangladesh: observation from four different diarrheal disease hospitals","volume":"8","author":"Das","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0450","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciu468","article-title":"Shigella isolates from the Global Enteric Multicenter Study Inform Vaccine Development","volume":"59","author":"Livio","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0455","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/infdis\/164.3.533","article-title":"Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei","volume":"164","author":"Formal","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0460","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/infdis\/125.1.12","article-title":"Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection","volume":"125","author":"DuPont","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0465","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0264-410X(95)00102-7","article-title":"A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity","volume":"13","author":"Kotloff","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0470","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4269\/ajtmh.2004.71.367","article-title":"Epidemiology of Shigella-associated diarrhea in rural Egyptian children","volume":"71","author":"Abu-Elyazeed","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0475","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/oxfordjournals.aje.a116134","article-title":"Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile","volume":"134","author":"Ferreccio","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0480","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/infdis\/157.5.1068","article-title":"Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population","volume":"157","author":"Cohen","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0485","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/jcm.29.2.386-389.1991","article-title":"Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis","volume":"29","author":"Cohen","year":"1991","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0490","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrmicro1662","article-title":"Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road","volume":"5","author":"Levine","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0495","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clim.2011.02.003","article-title":"Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates","volume":"139","author":"Simon","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0500","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/erv.12.135","article-title":"Recent progress towards development of a Shigella vaccine","volume":"12","author":"Camacho","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0505","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1586\/erv.09.127","article-title":"Inactivated and subunit vaccines to prevent shigellosis","volume":"8","author":"Kaminski","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0510","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1586\/14760584.5.5.669","article-title":"Live-attenuated Shigella vaccines","volume":"5","author":"Venkatesan","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0515","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.vaccine.2014.11.049","article-title":"An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children","volume":"33","author":"Walker","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0520","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1128\/CMR.00032-07","article-title":"Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion","volume":"21","author":"Schroeder","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0525","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fimmu.2015.00219","article-title":"Shigella manipulates host immune responses by delivering effector proteins with specific roles","volume":"6","author":"Ashida","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0530","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/sj.icb7100025","article-title":"Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival","volume":"85","author":"Phalipon","year":"2007","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0535","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrgastro.2013.12","article-title":"Progress and pitfalls in Shigella vaccine research","volume":"10","author":"Barry","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0540","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clim.2011.02.003","article-title":"Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates","volume":"139","author":"Simon","year":"2011","journal-title":"Clin Immunol (Orlando, Fla)"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0545","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4049\/jimmunol.164.4.2221","article-title":"Production of IFN-\u03b3 and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae Type 1 strain","volume":"164","author":"Samandari","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0550","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1128\/CVI.00115-14","article-title":"Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines","volume":"21","author":"Boyd","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0555","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1128\/CVI.00112-06","article-title":"Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies","volume":"13","author":"Burton","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0560","series-title":"Functional antibodies against Shigella and their association with protection against disease in humans","author":"Shimanovich","year":"2015"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0565","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1128\/iai.59.11.4075-4083.1991","article-title":"Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains","volume":"59","author":"Hartman","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0570","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1128\/iai.62.2.412-420.1994","article-title":"Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines","volume":"62","author":"Hartman","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0575","first-page":"293","article-title":"Experimental Shigella keratoconjunctivitis; a preliminary report","volume":"2","author":"Sereny","year":"1955","journal-title":"Acta Microbiol Acad Sci Hung"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0580","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0264-410X(93)90016-Q","article-title":"Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model","volume":"11","author":"Mallett","year":"1993","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0585","first-page":"54","article-title":"A challenge model for Shigella dysenteriae 1 in cynomolgus monkeys (Macaca fascicularis)","volume":"60","author":"Shipley","year":"2010","journal-title":"Comp Med"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0590","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1086\/650995","article-title":"A piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1","volume":"201","author":"Jeong","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0595","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.4049\/jimmunol.178.4.2476","article-title":"New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies","volume":"178","author":"Shim","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0600","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1016\/j.vaccine.2012.09.061","article-title":"Establishment of a Shigella sonnei human challenge model in Thailand","volume":"30","author":"Bodhidatta","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0605","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1017\/S0950268812001677","article-title":"The Shigella human challenge model","volume":"141","author":"Porter","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0610","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/00365549009027046","article-title":"Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes","volume":"22","author":"Ruuska","year":"1990","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0615","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1016\/j.vaccine.2009.06.107","article-title":"Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis","volume":"27","author":"Gaston","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0620","doi-asserted-by":"crossref","first-page":"e1001147","DOI":"10.1371\/journal.ppat.1001147","article-title":"Enhancing oral vaccine potency by targeting intestinal M cells","volume":"6","author":"Azizi","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0625","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3109\/08830180903236486","article-title":"Immunomodulation of gut-associated lymphoid tissue: current perspectives","volume":"28","author":"Luongo","year":"2009","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0630","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/S0264-410X(00)00553-3","article-title":"Mucosal vaccines: nontoxic derivatives of LT and CT as mucosal adjuvants","volume":"19","author":"Pizza","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0635","unstructured":"Clements JD. Double mutant enterotoxin for use as an adjuvant. Google Patents (1999)."},{"key":"10.1016\/j.vaccine.2016.02.075_bib0640","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1128\/CVI.00464-13","article-title":"Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli","volume":"20","author":"El-Kamary","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0645","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/CVI.00538-10","article-title":"Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G\/L211A), as a safe and effective oral adjuvant","volume":"18","author":"Norton","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0650","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.coi.2011.03.009","article-title":"Defending the mucosa: adjuvant and carrier formulations for mucosal immunity","volume":"23","author":"Lawson","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0655","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/vaccines3010148","article-title":"Choice and design of adjuvants for parenteral and mucosal vaccines","volume":"3","author":"Savelkoul","year":"2015","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0660","doi-asserted-by":"crossref","first-page":"8027","DOI":"10.1128\/IAI.73.12.8027-8032.2005","article-title":"Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers","volume":"73","author":"Orr","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0665","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/hv.4746","article-title":"Safety and immunogenicity of CVD 1208S, a live, oral \u0394guaBA \u0394sen \u0394set Shigella flexneri 2a vaccine grown on animal-free media","volume":"3","author":"Kotloff","year":"2007","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0670","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/IAI.00533-09","article-title":"Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants","volume":"78","author":"Ranallo","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0675","unstructured":"Nagy G, Henics T, Szuarto V, Nagy E. A novel live attenuated shigella vaccine. Google Patents (2014)."},{"key":"10.1016\/j.vaccine.2016.02.075_bib0680","series-title":"Development of a broad-spectrum vaccine against Shigellosis","author":"Kim","year":"2015"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0685","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1128\/iai.55.11.2797-2801.1987","article-title":"Introduction of Shigella flexneri 2a type and group antigen genes into oral typhoid vaccine strain Salmonella typhi Ty21a","volume":"55","author":"Baron","year":"1987","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0690","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijmm.2013.01.001","article-title":"Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a","volume":"303","author":"Dharmasena","year":"2013","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0695","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/CVI.00683-13","article-title":"Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine","volume":"21","author":"Kaminski","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0700","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1016\/j.vaccine.2005.07.014","article-title":"Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial","volume":"24","author":"McKenzie","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0705","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijmm.2013.02.017","article-title":"Cross-protection provided by live Shigella mutants lacking major antigens","volume":"303","author":"Szijarto","year":"2013","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0710","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/IAI.69.3.1351-1357.2001","article-title":"Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel","volume":"69","author":"Passwell","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0715","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1\u20134-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0720","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/chem.200400903","article-title":"Synthesis of two linear PADRE conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection","volume":"11","author":"B\u00e9lot","year":"2005","journal-title":"Chemistry \u2013 Eur J"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0725","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12934-015-0195-7","article-title":"In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation","volume":"14","author":"K\u00e4mpf","year":"2015","journal-title":"Microbial Cell Fact"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0730","first-page":"487","article-title":"Parenteral adjuvant effects of an enterotoxigenic Escherichia coli natural heat-labile toxin variant","volume":"4","author":"Braga","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0735","unstructured":"Oaks EV, Turbyfill KR, Kaminski RW. Artificial invaplex. Google Patents (2014)."},{"key":"10.1016\/j.vaccine.2016.02.075_bib0740","doi-asserted-by":"crossref","first-page":"24922","DOI":"10.1074\/jbc.M114.566570","article-title":"Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid a modifications: relative activation of TLR4 and TLR2 pathways in different mutants","volume":"289","author":"Rossi","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0745","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/IAI.06174-11","article-title":"Broadly protective Shigella vaccine based on type III secretion apparatus proteins","volume":"80","author":"Martinez-Becerra","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0750","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1016\/j.vaccine.2013.05.100","article-title":"Outer membrane protein A (OmpA) from Shigella flexneri 2a: a promising subunit vaccine candidate","volume":"31","author":"Pore","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0755","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijmm.2013.02.017","article-title":"Cross-protection provided by live Shigella mutants lacking major antigens","volume":"303","author":"Szij\u00e1rt\u00f3","year":"2013","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0760","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1073\/pnas.96.9.5194","article-title":"Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1","volume":"96","author":"Pozsgay","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0765","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.vaccine.2007.12.040","article-title":"Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a","volume":"26","author":"Turbyfill","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.02.075_bib0770","doi-asserted-by":"crossref","first-page":"e35616","DOI":"10.1371\/journal.pone.0035616","article-title":"High yield production process for Shigella outer membrane particles","volume":"7","author":"Berlanda Scorza","year":"2012","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16002863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16002863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T07:03:28Z","timestamp":1717225408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16002863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":77,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0264410X16002863"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.02.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Status of vaccine research and development for Shigella","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.02.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 World Health Organization; licensee Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}